Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: biostruggle who wrote (3577)	11/15/2002 2:20:25 PM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Marvin Somehow, I sometimes get the feeling that you like to see everything that has to do with Elan under a big black cloud. The PR doesn't actually say that Elan is backing away. It says that the trials will continue outside the structure of the present J/V. Elan has evidently decided that as the market doesn't like the J/Vs, they will not be bothered with J/Vs. As for CeNeS, they will not be able to fund this trial on their own. Only with continued financial support from Elan will they be able to bring these trials to a conclusion. Good or bad? We don't know yet. Time will tell. As for Antegren becoming a niche product in neurology. It depends to a large extent how one defines a niche. If they succeed, it will in my book be huge. If they don't, it will - as Bill likes to indicate - become a completely new ball game. Erik